In response to a recent press release issued by SourceOne Global Partners regarding a suit filed against KGK Synergize, the following statement was released today by KGK:
KGK will enforce its proprietary rights, including those associated with SYTRINOL®, whether it does so in a direct suit or by virtue of counterclaims in a declaratory judgment action brought by an infringer. It is important to our industry that we require companies to respect our contracts, patents and trademarks.
About KGK Synergize Inc:
KGK provides contract research services to the health nutrition, biotechnology and pharmaceutical industries. These services include both pre-clinical and human clinical trials.
In addition to its contract research capabilities, KGK has a Product Development Division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol® for cardiovascular health, DiabetinolTM for the treatment and/or prevention of Type II Diabetes, and DermytolTM, a new product for the protection of sun damage to the skin.